crizotinib - Profile

What are the generic sources for crizotinib and what is the scope of patent protection?

Crizotinib is the generic ingredient in one branded drug marketed by Pf Prism Cv and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Crizotinib has one hundred and five patent family members in forty-six countries.

Summary for crizotinib

International Patents:	105
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for crizotinib

Constraining patent/regulatory exclusivity:

8,217,057

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

8,217,057

Dosage:

CAPSULE, PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for crizotinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No	7,825,137
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No	7,858,643		Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No	8,217,057			Y

Expired US Patents for crizotinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023	7,230,098
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011	8,785,632
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-003	Sep 7, 2023	8,785,632

EU/EMA Drug Approvals for crizotinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Xalkori	crizotinib	EMEA/H/C/002489XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to	Authorised	no	no	no	2012-10-23

International Patents for crizotinib

Country	Patent Number	Title	Estimated Expiration
Spain	2353821
Cyprus	1113843
European Patent Office	1786785	COMPOSES D'AMINOHETEROARYLE ENANTIOMERIQUEMENT PURS UTILISES COMME INHIBITEURS DE PROTEINE KINASE (ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS)

Supplementary Protection Certificates for crizotinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	C 2013 011	Romania		PRODUCT NAME: CRIZOTINIB, OPTIONAL IN FORMA DE SARE ACCEPTABILAFARMACEUTIC, HIDRAT SAU SOLVAT AL ACE EU/1/12/793/004; DATE OF NATIONAL AUTHORISATION: 20121023; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/793/001, EMEA EU/1/12/793/002, EMEA EU/1/12/793/003, EMEA EU/1/12/793/004; DATE OF FIRST AUTHORISATION IN EEA: 20121023 STUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/793/001, RO EU/1/12/793/002, RO EU/1/12/793/003, RO
1786785	C01786785/01	Switzerland		FORMER OWNER: PFIZER INC., US
1786785	122013000027	Germany		PRODUCT NAME: CRIZOTINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023

Crizotinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Crizotinib, marketed as Xalkori, is a targeted tyrosine kinase inhibitor developed by Pfizer for the treatment of specific types of non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements. Since its approval in 2011, crizotinib has demonstrated substantial clinical benefits, but evolving market dynamics, patent expiration timelines, and emerging therapies influence its investment potential. This report analyzes currently available data to forecast its market trajectory, highlighting key drivers, competitive landscape, revenue forecasts, and risks to investors.

---

What Is the Current Market Position and Revenue Profile of Crizotinib?

Aspect	Details	Source / Data Year
Global Sales (2022)	Approx. $1.1 billion	IQVIA, 2022
Primary Indication	ALK-positive NSCLC, ROS1-positive NSCLC	FDA, 2011 onward
Sales Breakdown	US: 55%, Europe: 25%, Rest: 20%	IQVIA, 2022
Market Share	Leading targeted therapy for ALK NSCLC (approx. 60%)	EvaluatePharma, 2022
Patent Expiry	U.S. patent expiry projected in 2027	Pfizer filings, 2022

Key note: Crizotinib remains a top competitor in its niche but faces erosion as new therapies emerge.

---

What Are the Market Drivers and Constraints for Crizotinib?

Market Drivers

Driver	Impact	Evidence / Data
Prevalence of ALK-positive NSCLC	High unmet need, expanding patient base	Estimated >5% of NSCLC (~50,000 US patients)	[1]
Diagnostic Testing Adoption	Improves detection and prescription rates	Increasing use of FISH and NGS testing	[2]
Regulatory Approvals for Expanded Use	Broader indications (e.g., ROS1, CNS metastases)	Expanded FDA approvals (2016-2021)	[3]
Competitor Pipeline Activity	Sustains demand via alternative agents	ALK inhibitors like ceritinib, brigatinib, lorlatinib	[4]

Constraints

Constraint	Impact	Evidence / Data
Patent Erosion	Generic entry risk post-2027 in key markets	Patent expiry planned, generics likely within 2-3 years	[5]
Emergence of Next-Generation Therapies	Reduced market share	Lorlatinib (Pfizer), brigatinib gains market share	[6]
Pricing and Reimbursement Policies	Pressure on margins	Cost-containment efforts in US/EU	[7]
Resistance Development	Clinical mitigation needed	Over time, resistance mutations observed	[8]

---

What Is the Competitive Landscape and Emerging Alternatives?

Competitor / Therapy	Mechanism of Action	Indication	Key Differentiators	Status	Market Share Approx.
Ceritinib (LDK378)	ALK inhibitor	ALK-positive NSCLC	CNS activity	Approved, secondary	15-20% (2022)
Alectinib (Alecensa)	ALK inhibitor	First-line ALK NSCLC	Superior efficacy	Approved	25% (2022)
Lorlatinib (Lorbrena)	Third-generation ALK inhibitor	ALK resistance cases	CNS penetration	Approved	10-15% (2022)
Entrectinib & NTRK inhibitors	RNA fusion inhibitors	ROS1-positive NSCLC	Broader targets	Approved	Niche

Implication: Crizotinib is gradually ceding ground to newer, more potent agents with better CNS activity and resistance profiles.

---

What Are the Financial Trajectories and Revenue Forecasts for Crizotinib?

Forecast Assumptions

• Patent expiry in 2027, leading to generic entry.
• Sales gradually decline at an annual rate of around 20%, starting from peak revenues (~$1.1 billion in 2022).
• Market share decreases as alternatives gain approval.
• Accelerated adoption of next-generation ALK inhibitors.

Revenue Forecast Table (2023-2030)

Year	Estimated Sales (USD millions)	Notes
2023	900	Slight decline from 2022
2024	720	Market penetration of competitors
2025	576	Pre-patent expiry sales decline
2026	460	Pre-expiry continued erosion
2027	180	Patent expires mid-year
2028	90	Generic competition impact
2029	45	Further decline
2030	22	Market exhaustion

Note: Variability depends on regulatory delays, patent litigation, and adoption rates of competitors.

---

What Is the Investment Outlook and Risks?

Potential Opportunities

• Licensing deals for biosimilars or generics (pre-2027).
• Expansion into additional indications or markets.
• Integration with diagnostic tools for personalized therapy.

Risks

• Accelerated patent invalidation or legal challenges.
• Wariness in reimbursement for high-cost targeted therapies.
• Rapid succession by next-generation ALK inhibitors diminishing long-term revenues.
• Market entry of competing therapies offering superior benefit-risk profiles.

Strategic Recommendations

• Monitor patent litigations and regulatory pathways.
• Invest in R&D to extend drug lifecycle via combination therapies.
• Diversify portfolio with next-generation agents.

---

Comparison Table: Crizotinib vs. Key Competitors

Aspect	Crizotinib	Alectinib	Lorlatinib	Brigatinib
Approval Year	2011	2017	2018	2018
CNS Penetration	Moderate	High	High	High
Resistance Profile	Moderate	Better	Best	Good
Market Share (2022)	~60%	25%	10-15%	10-15%
Patent Status	Expiring 2027	Active	Active	Active

---

Frequently Asked Questions (FAQs)

1. When will generic versions of crizotinib likely enter the market?
Generic entry is expected post-2027, contingent on patent litigation. Market entry may be accelerated if patent challenges succeed.

2. How does crizotinib compare to next-generation ALK inhibitors?
Next-generation agents (e.g., lorlatinib) typically have superior CNS activity, resistance coverage, and efficacy, often replacing crizotinib in clinical use.

3. What are the key drivers affecting crizotinib's market decline?
Patent expiration, competing therapies with better profiles, and increased diagnostic penetration accelerate its decline.

4. Are there therapeutic combination strategies to sustain crizotinib’s market?
Yes. Combining crizotinib with other agents could improve resistance profiles and extend efficacy, but regulatory approval and clinical validation are required.

5. What emerging indications could prolong crizotinib’s commercial lifecycle?
Potential expansion into ROS1-positive NSCLC and other rare gene-rearranged tumors offers limited but strategic growth avenues.

---

Key Takeaways

• Current Value: Crizotinib maintains substantial revenue (~$1.1B in 2022) but faces imminent patent expiry in key markets by 2027.
• Market Dynamics: The rise of second- and third-generation ALK inhibitors with enhanced efficacy and CNS activity pose competitive threats.
• Investment Risks: Patent cliff, accelerated generic launches, and rapid drug pipeline evolution increase risk; thorough patent/legal monitoring is vital.
• Strategic Opportunities: Licensing, combination therapies, and diagnostic integration could mitigate revenue decline.
• Long-term Outlook: Expect significant revenue reduction by 2028, with a shift toward newer competitors and post-patent generic products dominating the landscape.

---

References

[1] National Cancer Institute. (2022). ALK-Positive NSCLC Statistics.
[2] FDA. (2021). Diagnostic Testing for Lung Cancer.
[3] FDA. (2016-2021). List of Approved Indications for Crizotinib.
[4] EvaluatePharma. (2022). Targeted NSCLC Therapies Market Share Analysis.
[5] Pfizer. (2022). Patent filings and expiry timelines.
[6] American Society of Clinical Oncology. (2022). ALK inhibitor clinical trials overview.
[7] CMS Reimbursement Policies. (2022). Reimbursement for Targeted Therapies.
[8] Clinical Oncology Research. (2021). Resistance Mechanisms in ALK Inhibitors.

Note: Data are based on recent industry reports, FDA filings, and scholarly publications as of 2022.